Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
Unveiling the role of circulating periostin in patients with idiopathic pulmonary fibrosis: A prognostic meta-analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alghwyeen Wasfi, Mohamed Shrouk F, Hashim Ahmed Shamil, Tawfik Abdelrahman M, Kertam Ahmed
Аннотация
BACKGROUND: Periostin measurement has been suggested as a noninvasive biomarker for assessing the likelihood of IPF progression and predicting patient outcomes, but these results aren't entirely consistent. Therefore, we conducted a meta-analysis to study the relation between serum periostin and IPF.
METHODS: We conducted a comprehensive search in major electronic biomedical databases of (PubMed, Scopus, Cochrane Library, EMBASE and Web of Science) spanning from inception to September 2024. Meta-analysis of included studies was done, and quantitative data were pooled as standardized mean difference (SMD), odd rations (ORs) and coefficient (r) values , with corresponding 95% confidence intervals (CIs).
RESULTS: Eleven articles were included in final meta-analysis. Our results showed that there was no significant difference in periostin levels between IPF patients and healthy controls (SMD: 2.59, 95% CI: -0.59 to 5.77, p= 0.11). Moreover, it was shown that IPF patients with a progressive disease have higher periostin levels compared to those who remain stable (SMD: 0.52, 95% CI: 0.29 to 0.75, p<0.0001). In addition to, higher serum periostin levels were significantly associated with shortened overall survival among IPF patients (RR: 3.70, 95% CI: 1.84 to 7.43, p<0.0001). Finally, there was a significant negative correlation between periostin levels and relative decline in DLCO and VC over the follow-up period (COR: -0.36, 95% CI, -0.58 to -0.10), (COR: -0.49, 95% CI, -0.63 to -0.34) respectively.
CONCLUSIONS: This study concludes that periostin may be a valuable biomarker for predicting prognosis in IPF patients.
METHODS: We conducted a comprehensive search in major electronic biomedical databases of (PubMed, Scopus, Cochrane Library, EMBASE and Web of Science) spanning from inception to September 2024. Meta-analysis of included studies was done, and quantitative data were pooled as standardized mean difference (SMD), odd rations (ORs) and coefficient (r) values , with corresponding 95% confidence intervals (CIs).
RESULTS: Eleven articles were included in final meta-analysis. Our results showed that there was no significant difference in periostin levels between IPF patients and healthy controls (SMD: 2.59, 95% CI: -0.59 to 5.77, p= 0.11). Moreover, it was shown that IPF patients with a progressive disease have higher periostin levels compared to those who remain stable (SMD: 0.52, 95% CI: 0.29 to 0.75, p<0.0001). In addition to, higher serum periostin levels were significantly associated with shortened overall survival among IPF patients (RR: 3.70, 95% CI: 1.84 to 7.43, p<0.0001). Finally, there was a significant negative correlation between periostin levels and relative decline in DLCO and VC over the follow-up period (COR: -0.36, 95% CI, -0.58 to -0.10), (COR: -0.49, 95% CI, -0.63 to -0.34) respectively.
CONCLUSIONS: This study concludes that periostin may be a valuable biomarker for predicting prognosis in IPF patients.